07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Breckenridge sales and marketing update

Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the U.S. The antihistamine is approved to treat seasonal allergic rhinitis in patients at least five years...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Dymista azelastine/fluticasone regulatory update

FDA approved an sNDA from Meda for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients ages 6-11 who require treatment with both components. In 2012, FDA approved the product -- a combination of azelastine...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Acton Pharmaceuticals, Meda deal

Meda will acquire Acton for $135 million in cash plus a $10 million near-term undisclosed development milestone. Acton is also eligible for sales-based milestones, which the company said may bring the total deal value up...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Cipla, Meda sales and marketing update

Cipla and Meda added full rights in Latin and South America, the Middle East, Africa and Asia to 2008 and 2009 deals granting Meda exclusive rights to develop and commercialize Cipla's Dymista azelastine/fluticasone in...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

Dymista azelastine/fluticasone regulatory update

Meda said the Swedish Dental and Pharmaceutical Benefits Agency will reimburse Dymista azelastine/fluticasone to treat seasonal and perennial allergic rhinitis. The product was approved under the EU's decentralized procedure in January and is reimbursed in...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps were...
08:00 , Jan 28, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) lost $2.74 to $94.68 last week after announcing the U.K. Ministers of Health deferred a decision to cover Soliris eculizumab on the NHS for atypical hemolytic uremic syndrome (aHUS). According...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

Dymista azelastine/fluticasone regulatory update

Meda said its Dymista azelastine/fluticasone was approved under the EU's decentralized procedure to treat seasonal and perennial allergic rhinitis. Germany acted as the reference member state. Meda plans to launch Dymista in Europe this year....
01:57 , Jan 25, 2013 |  BC Extra  |  Company News

Meda's Dymista approved for allergic rhinitis

Meda AB (SSE:MEDAA) said its Dymista azelastine/fluticasone was approved under the EU's decentralized procedure to treat seasonal and perennial allergic rhinitis. Germany acted as the reference member state. Meda plans to launch the product in...